Picornaviruses are attractive experimental models for basic studies on protein structure and function. The protein shell has particularly simple architecture, 60 subunits organized as 12 pentamers, and the atomic structure of the protein subunit is now known for three of them: human rhinovirus 14 (HRV14), type 1 poliovirus (PV1) and mengovirus. Using a panel of 35 neutralizing monoclonal antibodies and 62 escape mutant we have identified four neutralization sites on HRV 14. In a parallel study we have used 15 neutralizing monoclonal antibodies to identify three neutralization sites on the Sabin strain of PV1. We believe that we have picked up a correlation between the shape of the neutralization curve produced by an antibody and the location of its binding site on the virus surface. The results suggest that spanning distance between sites across a 2-fold symmetry axis may be responsible for the correlation. We will extend our studies to determine the strength of the correlation and will apply the antibodies and mutants developed in this work toward a systematic comparative study on mechanisms of picornavirus neutralization and assembly. Selected antibodies will be sent to Purdue University of crystallographic determination of the 3- dimensional structure of the binding site. We sill study a new class of drugs (WIN drugs) which neutralize picornaviruses by binding to a pocket inside VP1. We have identified three classes of drug-resistant mutants of HRV14; H- mutants (able to grow at high drug concentrations (6 Mug/ml); L- mutants (able to grow at low concentrations (at 0.3 Mug/ml but not at 6 Mug/ml); and D-mutants which depend upon the drug for growth. We will assemble a collection of independent mutant of each class and identify the responsible amino acid alteration. We will use these mutants and wild type virus to examine the effect of the drug on a variety of physical properties including pH stability, permeability to cesium ion and isoelectric A-B transition. Selected mutants will be analyzed by x-ray crystallography at Purdue University to determine the effect of the mutation on the 3-dimensional structure of the pocket.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI024939-02
Application #
3138209
Study Section
Virology Study Section (VR)
Project Start
1987-07-01
Project End
1992-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Graduate Schools
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Lee, W M; Monroe, S S; Rueckert, R R (1993) Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol 67:2110-22
Smith, T J; Olson, N H; Cheng, R H et al. (1993) Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J Virol 67:1148-58
Shepard, D A; Heinz, B A; Rueckert, R R (1993) WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J Virol 67:2245-54
Vrijsen, R; Mosser, A; Boeye, A (1993) Postabsorption neutralization of poliovirus. J Virol 67:3126-33
Mosser, A G; Rueckert, R R (1993) WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol 67:1246-54
Giranda, V L; Heinz, B A; Oliveira, M A et al. (1992) Acid-induced structural changes in human rhinovirus 14: possible role in uncoating. Proc Natl Acad Sci U S A 89:10213-7
Jewell, J E; Ball, L A; Rueckert, R (1990) Limited expression of poliovirus by vaccinia virus recombinants due to inhibition of the vector by proteinase 2A. J Virol 64:1388-93
Colonno, R J; Callahan, P L; Leippe, D M et al. (1989) Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 63:36-42
Heinz, B A; Rueckert, R R; Shepard, D A et al. (1989) Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol 63:2476-85
Page, G S; Mosser, A G; Hogle, J M et al. (1988) Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol 62:1781-94